Albendazole vs Triclabendazole — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Anthelmintic

Albendazole

Brand: ALBENZA

First FDA approval: 1996-06-11

Anthelmintic

Triclabendazole

Brand: EGATEN

First FDA approval: 2019-02-13

Lowest NADACAcquisition cost floor across all NDCs

$4.40Per unit

—Per unit

Average NADACAcross all dosage forms and strengths

$4.40Up to $4.40

—

Generic manufacturersActive ANDA holders — FDA Orange Book

66 total ANDAs filed

00 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$7.8MFull year

—Full year

Part D claims (CY24)Total fills, all strengths

19K14K beneficiaries

—— beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$414Per claim, all NDCs

—Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

52Minimal friction

—Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

—None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes6 manufacturers

NoBrand-only